Yes. Thank you to the member for his question.
I'll begin and then very quickly—I'm thoughtful of the time—hand it to my colleagues, who in fact are the experts doing this day to day.
It is very much the case that we work to make sure, right through the clinical trial approval stage, through the drug approval stage, and then in the post-market stage, that we are looking at safety at every step. We post, as my colleague mentioned, the product information on the web so that individual practitioners and Canadians can see it. We post advisories, wherever we have concerns. We have mechanisms to determine which signals might be ones we should be prioritizing.
I'll turn to my colleagues for a more complete answer.